Drugs / TriCAR-T-CD19
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03497533 | Aug 2018 → Dec 2020 | B-cell non-Hodgkin lymphoma | Timmune Biotech Inc. | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TriCAR-T-CD19 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03497533 ↗ |
| Action | Deplete | “enabling the TriCAR-T-CD19 to simultaneously targeting the CD19 positive NHL” NCT03497533 ↗ |
| Modality | Cell therapy | “an autologous tri-functional anti-CD19 chimeric antigen receptor (CAR)-positive T cell therapy” NCT03497533 ↗ |
| Route | Intravenous | “Tri-functional anti-CD19 chimeric antigen receptor transduced autologous T cells will be administered intravenously” NCT03497533 ↗ |
| Target | CD19 | “The tri-functional anti-CD19 chimeric antigen receptor contains an anti-CD19 scFv” NCT03497533 ↗ |